chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from the authors of the published literature article. The authors used Social Media's Public Streams Application Programming Interface (API) to collect live data. Between November of 2014 and January 2015, they systematically endeavored to select an optimal set of terms that would be parsimonious enough to be feasible yet broad enough to capture sufficient relevant information. Of the 2,000 comments, 1,887 (94.4%) were relevant to human papillomavirus (HPV). Thus, these 1,887 comments composed their final data-set. The vast majority of comments (n=1,668, 88.4%) originated from unique user accounts. Two hundred and four comments (10.8%) were from users who posted between two and five times, and 30 (1.6%) were from users who posted 10 or more times. Ninety-five (5.0%) comments were coded as having negative sentiment. These comments generally discouraged GARDASIL or GARDASIL 9 vaccination or expressed a particularly negative view toward it. Specific terms characteristic of these comments included "beware," "destroys lives," and "mystery illness." While sentiments were nearly always directly incorporated in to the comments themselves, negative sentiment could also often be inferred by the hashtags at the end of the comment. 78 (4.1%) comments explicitly claimed lack of safety. Examples of phrases included in comments describing lack of safety included "GARDASIL or GARDASIL 9 ruins live [sic]" and "girl dies shortly after receiving HPV vaccine." This case concerns to a healthy 12-year-old girl who died shortly after receiving HPV vaccine. The case was coded as lack of safety 77 (4.1%). The reporter considered death to be related to GARDASIL 9 and/or GARDASIL. Upon internal review death was considered to be a medically significant event. This is one of 2 reports derived from the same literature source, linked to case # 1801USA003508. Sender's Comments: US-009507513-1801USA003508.
After second whole body broke out in scabies like sores all over body, still has sores today, some broke open and got infected; After second whole body broke out in scabies like sores all over body, still has sores today, some broke open and got infected/Severe body aches; After second whole body broke out in scabies like sores all over body, still has sores today, some broke open and got infected; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 58-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 22Feb2022 as dose 2, single (Lot number: FM0698) at the age of 58 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Heart attack", start date: Jul2021 (unspecified if ongoing), notes: Heart attack Jul2021; "Known allergies: sulfa" (unspecified if ongoing), notes: Known allergies: sulfa; "COVID-19" (unspecified if ongoing), notes: Prior to vaccination, the patient was diagnosed with COVID-19. The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (Dose: 01, prev dose lot number=FE3592, Prev dose vaccine location= Left arm), administration date: 27Jan2022, when the patient was 58-year-old, for COVID-19 Immunization, reaction(s): "Left arm swelled up after first dosage". The following information was reported: ACARODERMATITIS (disability), INFECTION (disability) all with onset 22Feb2022, outcome "not recovered" and all described as "After second whole body broke out in scabies like sores all over body, still has sores today, some broke open and got infected"; PAIN (disability) with onset 22Feb2022, outcome "not recovered", described as "After second whole body broke out in scabies like sores all over body, still has sores today, some broke open and got infected/Severe body aches". The events "after second whole body broke out in scabies like sores all over body, still has sores today, some broke open and got infected" and "after second whole body broke out in scabies like sores all over body, still has sores today, some broke open and got infected/severe body aches" required physician office visit. Therapeutic measures were not taken as a result of acarodermatitis, pain, infection. The report was assessed as serious and Seriousness criteria-Disabling/Incapacitating. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Left arm swelled up after first dosage after second whole body broke out in scabies like sores all over body, still has sores today, some broke open and got infected severe body aches after third, elbow blew up like a golf ball under it and turned black and blue. even worse body aches. Events resulted in: [Doctor or other healthcare professional office/clinic visit, Disability or permanent damage]. Since the vaccination, the patient has not been tested for COVID-19.
Tightness and soreness at the injection site; Tightness and soreness at the injection site; Tenderness in the corner of the mouth; This is a spontaneous report from a contactable consumer (patient). A 69-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration on 25Jan2021 as single dose for covid-19 immunisation. The patient medical history includes flu vaccine and shingles. Patients concomitant medications were not reported. The patient stated that when he got the flu vaccine and shingles he had tightness and soreness, but he did not feel anything after the covid shot. It was reported that he received pfizer covid vaccine 3 days ago and next dose is 15Feb. Patient experienced some side effects and he read that older people have severe side effects after the second dose. He experienced tightness and soreness at the injection site, tenderness in the corner of the mouth. He said it went away. He wanted to know about the severity of side effect and how effective the vaccine is. He also stated that he read that people are getting the infection after the first dose of the covid vaccine. he wanted to know if symptoms are going to be less severe after the vaccine and also wanted to know if he should be wearing double mask. Patient asked that is it true that you have about 50 % immunity after the 10 days of the first shot. On Jan2021, the patient experienced tightness and soreness at the injection site and tenderness in the corner of the mouth. Outcome of the events was recovered on an unspecified date.  Information about lot/batch number has been requested.  Follow-up attempts are completed. No further information is expected.
lip tingling started about 30 min after vaccine.  No other sx. Pt took Benadryl 25mg q6 hours x 24 hours.  No further episodes.
Information has been received from a mother, also a RN, concerning her son who at one year of age on an unknown date in 1997 was vaccinated with varicella virus vaccine live. The mother reported that she got the chickenpox when her son was three years old and two weeks after the start of her clinical symptoms, her son developed six Varicella like lesions. The mother reported that no treatment was needed and his lesions healed on their own. It was noted that the adverse event abated. At the time of this report her son is eight years old. There was no product quality complaint reported. No other information was provided at the time of this report. Unspecified medical attention was sought. Additional information has been requested.
Child had MMR, IPV & DTaP in 6/07.  Were given again 6/08.  Parents notified.
Flu Shot was given at work by outside nurse hired by our company. Since then I have been dizzy, flashes of heat flush in my body, severe and prolonged headaches, extreme fatigue, want to sleep all the time. Generally feeling just rundown all the time. I went to my doctor since then to make sure I'm OK. Before I got the shot I was just fine with lots of energy.
Since June, I have had fluid behind my left ear, left jaw pain, left eye discomfort. , sinus issues. I have had 3 rounds of antibiotics and 1 round of steroids.
Patient tested positive for COVID-19 on 2/4/21, she had symptoms of cough and sore throat on 2/2/21. She was admitted to hospital on 2/12/21 COVID-19 pneumonia and hypoxic respiratory failure.
arm was sore; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm was sore) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination.     The patient's medical history was not reported.  Concomitant products included VITAMINS NOS, CINNAMON [CINNAMOMUM VERUM], MAGNESIUM and TIMOLOL for an unknown indication.    On 22-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Feb-2021, the patient experienced PAIN IN EXTREMITY (arm was sore). At the time of the report, PAIN IN EXTREMITY (arm was sore) outcome was unknown.            Concomitant medication was not reported. The patient did not use any treatment medication.
Child with history of asthma. Became short of breath with cough and wheeze. Also red rash to face and neck.
Blurred vision; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2587) via an unspecified route of administration in the left arm on an unknown date in Oct2021 at 11:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 and unspecified allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date in Oct2021, the patient experienced blurred vision  for about 15 minutes. The event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event blurred vision was resolved on an unknown date in Oct2021.
This was my second Moderna in a series of 2. Had extreme body aches starting about 12 hours after initial injection. Those lasted approximately 24 hours.  Then starting 2 days after vaccine got a red, hot, sore rash on same arm that still hasn?t gone away and has gotten worse.
Mouth ulcers / canker sores. Occurred after dose 1 but was minor, though persistent. One or two that wouldn?t go away. The night of shot 2 and since, I?ve been incredibly bother but quickly forming canker sores that are lining my upper gums and inner upper lips. As of today, I count 6 active sores. I?ve also experienced lip swelling from a sore that eventually split the inside of my upper lip.   Note that I cannot recall ever really having a canker sore before and while correlation may not equal causation, it seems tied to the vaccine since it was already present after dose 1 and was then exacerbated by dose 2.
pt recv vax; was found to be pregnant; did not realize was pregnant at time of vax & chose to terminate the pregnancy;
Tingling; numbness under the arm and the side of the body; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (Tingling) and HYPOAESTHESIA (numbness under the arm and the side of the body) in a female patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PARAESTHESIA (Tingling) and HYPOAESTHESIA (numbness under the arm and the side of the body). At the time of the report, PARAESTHESIA (Tingling) and HYPOAESTHESIA (numbness under the arm and the side of the body) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Mammogram: ruled out anything pertaining to the breast. On an unknown date, Ultrasound breast: ruled out anything pertaining to the breast.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medicine were reported. Lab data contains Mammogram in Sep-2021 with unknown result. The patient also informed to the lab technician that she was experiencing a sensation under her left arm. The patient was told that this could also be related to her neck problem so she did PT for 3 months but it did not offer any relief. No treatment medicine were reported.
Hives began on my neck & traveled down trunk (front & back), inside ears, face, hands, itchy throat, ears, lips swollen, throat felt 'thick' nauseated, tongue felt thick, difficult to breath. ER started IV, gave me IV Benadryl, Pepcid, prednisone, Ativan. BP was 98/110, pulse 110..Sent me home with 5 days prednisone 50mg 1/d; 5 Pepcid 1/d, Benadryl.
Moderna Dose #1:   The only adverse event was a mild ache in my arm at the injection site.      Moderna Dose #2:   About 7 hours post-injection I experienced a temperature (101 F peak) and mild chills, a short-term mild headache, mild muscle /joint aches, and an ache at the injection site.  These effects lasted for about 36 hours and then were gone.  I would compare them to a mild 2-day case of the flu.
Information has been received from a medical assistant referring to a patient of unknown age and gender. Information about concurrent condition, medical history, drug reaction/allergies and concomitant therapy were not provided. The patient was vaccinated with the first dose of VAQTA on 18-JUL-2016 and the second dose on 08-DEC-2016 (strength, dose, lot # and expiration date was unknown) intramuscularly for prophylaxis, which was shorter than the recommended interval between doses. No adverse effect was reported by the patient. Additional information has been requested.
her arm bothering where they gave it, "it's swelling"; she's hurting; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). A 85 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), administration date: 23Mar2021, for COVID-19 immunization. The following information was reported: VACCINATION SITE SWELLING (non-serious), outcome "unknown", described as "her arm bothering where they gave it, "it's swelling""; PAIN (non-serious), outcome "unknown", described as "she's hurting". Therapeutic measures were taken as a result of vaccination site swelling, pain.  Additional information: Caller mother complained about events after second shot and patient used heating pad as a therapeutic measure and felt little better.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Day 8 after first dose noticed swelling, redness and itching in a 2 x 6 inch area around the injection site.  Also have headache and fatigue but not sure if they're related.
fever; Breathing problems; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Breathing problems) and PYREXIA (fever) in a 42-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 003A21A and 030L20A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma, Allergy, Smell loss (two years) and Taste loss (two years). Concomitant products included ALBUTEROL SULFATE and FORMOTEROL FUMARATE, MOMETASONE FUROATE (DULERA) for an unknown indication.   On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 06-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced DYSPNOEA (Breathing problems). On 08-Mar-2021, the patient experienced PYREXIA (fever). At the time of the report, DYSPNOEA (Breathing problems) and PYREXIA (fever) outcome was unknown.            Treatment medication included inhalers  Action taken with mRNA-1273 Moderna vaccine was Not Applicable   This case was linked to MOD-2021-038166 (Patient Link).
SC abscess at injection site above left deltoid. Incision and drainage performed on 9/29/06 with would culture. Pt started on Keflex 500mg QID #20. Soreness since vaccine administered, white, blood discharge since 9/28/06.
Narrative: Hospital, COVID +. moderna x 3, falls,  chest congestion, wheezing, UTI, COPD exacerbation, d/c to.
1 hour after receiving DTaP and MMR vaccines, mother called office with c/o hive rash on trunk with spread to neck/face; no respiratory Sx; to local ER by ambulance. Treated with Benadryl and Prednisone; unremarkable recovery; no hospitalization.
High fever (102) and chills. Lots of shivering and flushed face. Body aches and fatigue.0
I developed a loud ringing in my ears a few minutes after the injection and it has never stopped.  Still going on to this day
Patient falsified their DOB in order to qualify for the vaccination. It was not discovered until billing their vaccine and the third party rejected based on invalid DOB. When we called the insurance, they said the patient was born in 2005 and not 2004 as stated on their consent form.
Swollen lymph nodes under right arm; Armpit swelled up considerably and experienced lots of pain; Armpit swelled up considerably and experienced lots of pain; Hot to the touch; Soreness in arm; Aches and pains; 99 plus fever; Tiredness; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right  arm on 13Apr2021 at 17:30 (at the age of 55-year-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis, hypothyroidism, overweight and prior to the vaccination, the patient was diagnosed with COVID-19. The patient was allergic to sulfur meds (drug allergy). Concomitant medications included celecoxib (CELEBREX), levothyroxine sodium (SYNTHROID), vitamin d nos (VITAMIN D), sertraline (MANUFACTURER UNKNOWN) and phendimetrazine tartrate (PHENTRA) all for an unknown indication, from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021, after shot, the patient had soreness in arm, aches and pains, 99 plus (unspecified units) fever and tiredness; about 24 hours after shot at 18:00, the patient developed swollen lymph nodes under right arm, armpit swelled up considerably and experienced lots of pain and it was hot to the touch. At the time of this report (still), it was very swollen and painful 3 days after shot, no longer hot to the touch and the patient still experienced slight aches as well. Since the vaccination, the patient had been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported adverse events. The clinical outcome of the event hot to the touch was resolved on an unknown date in Apr2021, whereas the clinical outcome of the events soreness in arm, aches and pains, 99 plus fever, tiredness, swollen lymph nodes under right arm, armpit swelled up considerably and experienced lots of were not resolved at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Information has been received via telephone call from a medical assistant concerning an 86 year old female retired patient who on 07-MAY-2008 was vaccinated with a dose of ZOSTAVAX (Merck) (Lot # 659614/0161X, expire date not reported), subcutaneously in the right arm. Concomitant therapy included TRIAVIL, ATACAND, NORVASC, thyroid, hydrochlorothiazide, calcium (unspecified) (+) vitamin D (unspecified), flax seed, hydrocodone, vitamin E, Flora Source, fish oil, vitamin C and vitamin D3. Medical assistant stated that on 24-FEB-2011, the patient was seen in the office with a case of shingles. Medical assistant explained that it was the "worse case ever seen" and the patient had lesions everywhere. Physician's diagnosis was acute onset diffuse herpes zoster vesicular eruption dorsal 6&7 and also at L2&3 on the right side posterior. Medical assistant explained that the physician punctured one of the lesions on thoracic area mid clavic line T-6,7 to collect vesicular fluid for the sample for PCR studies. The patient was treated with famciclovir 500 mg three times a day for 7 days. At the time of the report, patient's outcome was unknown. Follow-up information received via telephone call from the medical assistant indicated that on 03-MAR-2011 the patient was seen in the office and was improving, but in a lot of pain. In the office discussed the option of treating her with hydrocodone for pain, however pain meds were not started at that point. The patient was enrolled in the Varicella Zoster Virus Identification Program to identify if VZV is present and if it is present, to identify if it is associated with the wild-type (WT) VZV strain or with the Merck vaccine strain. On 04-MAR-2011, the PCR results from the vesicular specimen (collected on 24-FEB-2011) showed that Varicella Zoster Virus DNA was not amplified as well as , B-globin DNA was not either. The specimen was inadequate, negative for B-globin and no strain was identified. A lesion sample was collected on 24-FEB-2011. The sample was taken from a swab. VZV DNA was amplified. On 18-MAR-2011, the PCR result from the swab specimen identified the presence of wild type strain. Follow-up information was received from a physician concerning a patient who in the morning of 07-MAY-2008 was vaccinated with the first dose of ZOSTAVAX (Merck) in the right deltoid. The physician stated that on 22-FEB-2011 at 11:00 (previously reported as 24-FEB-2011 by the medical assistant), the patient developed herpes zoster with left thoracic D-6-7 eruption that diffusely involved 2 levels. The physician mentioned that they attempted to send it for identification but it was apparently not enough or dry. The patient did not seek medical attention. At the time of the report, the patient recovered. Additional information is not expected.
Intussusception diagnosed by ultrasound reduced by air enema October 9th, 2013. Observed overnight, discharged home in good condition October 10th, 2013.